ACYCLOVIR; HYDROCORTISONE: Pharmaceutical manufacturers, suppliers, and packagers

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Bausch	XERESE	acyclovir; hydrocortisone	CREAM;TOPICAL	022436	NDA	Bausch Health US LLC	0187-5104-01	1 TUBE in 1 CARTON (0187-5104-01) / 5 g in 1 TUBE	2009-07-31
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: August 1, 2025

Overview of Acyclovir and Hydrocortisone

Acyclovir and hydrocortisone are widely used pharmaceuticals across multiple therapeutic categories. Acyclovir, an antiviral agent, is primarily prescribed for herpes infections, including herpes simplex and varicella-zoster viruses. Hydrocortisone, a corticosteroid, treats inflammatory and autoimmune conditions, such as eczema, psoriasis, and adrenal insufficiency.

Both drugs are essential in clinical settings, necessitating a reliable, high-quality supply chain. This article examines the leading suppliers, manufacturing landscape, and sourcing strategies for acyclovir and hydrocortisone, providing insights vital for pharmaceutical companies, healthcare providers, and policymakers.

1. Global Manufacturing and Supply Landscape

Acyclovir

Manufacturing Overview:
Acyclovir’s synthesis involves complex chemical processes, enabling its production at multiple facilities worldwide. Its high demand stems from its efficacy in treating viral infections. The primary manufacturing hubs are located in India, China, and developed markets such as the U.S., Europe, and Japan.

Key Suppliers:

Hetero Labs (India): A significant producer of generic acyclovir, supplying both tablets and injectables globally. Known for rigorous quality standards and adherence to WHO GMP guidelines.
Cipla (India): Offers a broad range of antiviral medications, including acyclovir, with robust export capabilities.
Maneesh Laboratories (India): Specialty manufacturer with a focus on antiviral drugs, including acyclovir.
Dr. Reddy’s Laboratories (India): Supplies acyclovir in multiple formulations, emphasizing affordable generics.
Sandoz (Novartis): Produces acyclovir generics with extensive international distribution networks.
GSK (UK): Historically involved in antiviral drug development, although its current production of acyclovir is limited and often reliant on licensed third-party manufacturers.

Manufacturing Challenges and Trends:
Despite the widespread generic manufacturing, supply chain disruptions can occur due to raw material shortages, regulatory shifts, or geopolitical issues. Indian manufacturers dominate due to cost competitiveness and local expertise. Ensuring supply continuity involves assessing manufacturer GMP compliance, capacity scalability, and global distribution reach.

Hydrocortisone

Manufacturing Overview:
Hydrocortisone (also known as cortisol) is produced through chemical synthesis or extraction from natural sources like adrenal tissue. The synthetic process involves multiple steps to achieve pharmaceutical-grade purity.

Leading Suppliers:

Pfizer: A primary supplier of hydrocortisone products globally, including injectable and topical formulations.
CordenPharma: Specializes in high-quality corticosteroids, including hydrocortisone, with production facilities in Europe and the U.S.
Kao Corporation: Offers hydrocortisone creams and topical formulations widely used in dermatology.
Xianju Pharmaceutical (China): A key Chinese manufacturer of corticosteroids, including hydrocortisone, supplying both domestic and export markets.
Sun Pharmaceutical Industries (India): Produces a range of corticosteroid products with expanding market share.
Teva Pharmaceuticals: Provides generic hydrocortisone, including injections and topical forms.

Market Dynamics and Trends:
Hydrocortisone manufacturing is sensitive to regulatory standards, as corticosteroids fall under strict quality controls. Competition among generic producers keeps prices competitive. The supply chain is internationally distributed, with notable manufacturing hubs in India, China, and Europe.

2. Raw Material and API Supply Chains

The backbone of acyclovir and hydrocortisone manufacturing hinges upon high-quality active pharmaceutical ingredients (APIs).

Acyclovir API Suppliers:

Hetero Labs: Also supplies acyclovir APIs directly, ensuring end-to-end control over quality.
Aurobindo Pharma: Supplies acyclovir APIs for global generic markets.
Husky Pharmaceutical (China): Manufactures and supplies acyclovir API with competitive pricing.

Hydrocortisone API Suppliers:

Xianju Pharmaceutical: Supplies hydrocortisone API for both domestic and international markets.
LGM Pharma: Distributes corticosteroid APIs globally, including hydrocortisone.
R-Pharm (Russia): Supplies APIs to European and Asian markets.

The API supply chain is characterized by the concentration of manufacturing in Asia, with regulatory scrutiny increasing around API standards. Manufacturers adhering to Good Manufacturing Practice (GMP) are deemed most reliable.

3. Regulatory Considerations and Quality Standards

Suppliers must comply with stringent regulatory frameworks, including:

FDA (U.S.): Approves manufacturing facilities for sale within the U.S., emphasizing Good Manufacturing Practices (GMP).
EMA (Europe): Enforces rigorous standards for pharmaceuticals sold within the EU.
World Health Organization (WHO): Certifies GMP compliance for suppliers targeting emerging markets.

Manufacturers with WHO-GMP certification are preferred, especially in markets demanding high-quality standards, such as India, China, and Latin America.

4. Strategic Sourcing and Supply Chain Risks

Securing a dependable supply of acyclovir and hydrocortisone demands diversification across multiple suppliers and geographic regions. Dependency on a limited number of suppliers, particularly in geopolitically volatile regions, heightens risks related to export restrictions, political instability, and raw material shortages.

Key strategies include:

Establishing multi-supplier contracts.
Engaging with API manufacturers directly to ensure supply chain transparency.
Monitoring regulatory developments affecting manufacturing licenses and export policies.
Incorporating supply chain risk assessments into procurement workflows.

5. Emerging Trends and Future Outlook

Increased Focus on Local Manufacturing:

Global manufacturing capacity for both drugs is expected to expand, driven by initiatives like India’s “Make in India” and China's pharma upgrade programs. Local manufacturing reduces dependency on imports, increases supply resilience, and aligns with government incentives.

Technological Innovations:

Advances in biotechnological methods and process optimization may streamline production, reduce costs, and improve quality consistency.

Regulatory Harmonization:

Global efforts to harmonize drug standards will facilitate smoother cross-border procurement, enhancing supply reliability.

Sustainability and Supply Chain Resilience:

Increasing emphasis is placed on sustainable manufacturing practices and establishing resilient supply chains amidst geopolitical and economic uncertainties.

Key Takeaways

Dominant Suppliers: Indian manufacturers such as Hetero Labs, Cipla, and Dr. Reddy’s lead in acyclovir supply; Pfizer, Sun Pharma, and Xianju Pharmaceutical are key hydrocortisone suppliers.
API Sources: Asia, especially China and India, remain central to API production, with suppliers adhering to international GMP standards critical for supply assurance.
Regulatory Compliance: Certification by entities like WHO, FDA, and EMA influences supplier credibility and market access.
Supply Chain Risks: Geopolitical tensions, raw material shortages, and regulatory changes can disrupt supply chains; diversification is essential.
Future Trends: Localized manufacturing, technological advances, and global harmonization efforts will shape the supply landscape for these critical drugs.

FAQs

1. Who are the main generic suppliers of acyclovir globally?
India’s Hetero Labs, Cipla, and Dr. Reddy’s are among the primary generic producers, with widespread export operations. Sandoz and GSK also supply acyclovir generics in certain markets.

2. Which countries dominate hydrocortisone manufacturing?
China, India, and European countries like Germany and Italy host significant hydrocortisone production facilities, with Chinese and Indian manufacturers expanding their global footprint.

3. How do regulatory standards influence supplier selection?
Suppliers with WHO-GMP, FDA, or EMA accreditation are preferred, as they demonstrate compliance with high-quality manufacturing practices, reducing risk of product recalls and regulatory hurdles.

4. What sourcing strategies mitigate supply chain disruptions for these drugs?
Diversification across multiple suppliers and regions, direct API sourcing, maintaining safety inventory levels, and monitoring geopolitical developments are critical strategies.

5. Are there emerging alternatives or innovations impacting the supply of acyclovir and hydrocortisone?
Yes. Novel formulations, biosimilars, and process innovations aim to improve efficacy, reduce costs, or enhance supply chain resilience, but their market penetration remains ongoing.

References

[1] World Health Organization. (2022). WHO Good Manufacturing Practices.
[2] IQVIA Institute. (2021). The Future of Global Supply Chains in Pharmaceuticals.
[3] U.S. Food and Drug Administration. (2022). List of Approved Drug Manufacturing Facilities.
[4] European Medicines Agency. (2022). Medicines and Manufacturing Standards.
[5] MarketWatch. (2022). Global Pharmaceutical Industry Report.

Suppliers and packagers for generic pharmaceutical drug: ACYCLOVIR; HYDROCORTISONE